Derek Johnson's questions to InflaRx (IFRX) leadership • Q3 2019
Question
Derek Johnson from Guggenheim Partners asked if any biomarker analysis had been conducted to identify patient subsets likely to respond, potentially to exclude nonresponders from future trials. He also requested clarification on the data in Slide 12, which appeared to show a number of IHS-4 responders in the original placebo group.
Answer
Executive Niels Riedemann explained that while the company is actively working on a biomarker that tracks treatment response, analysis to predict responders upfront has not been conducted yet. Regarding Slide 12, he clarified that the mean IHS-4 response shown for the placebo-transitioned group was skewed by a few patients with an extremely good response and directed attention to Slide 7 for a more representative view of the overall placebo group's performance, highlighting the risk of being fooled by small patient numbers.